{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:58:37Z","timestamp":1781067517677,"version":"3.54.1"},"reference-count":166,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000303","name":"Inspire Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000303","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["DST\/INSPIRE Fellowship\/IF210302"],"award-info":[{"award-number":["DST\/INSPIRE Fellowship\/IF210302"]}],"id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.bcp.2025.117534","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T16:51:00Z","timestamp":1762534260000},"page":"117534","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P2","title":["Unfolding the role of HDAC2 in the epigenetic puzzle of cancer: A dive into molecular pathways for precision-driven multi-target therapy"],"prefix":"10.1016","volume":"243","author":[{"given":"Kakali","family":"Sarkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Debbarma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shayanika","family":"Debnath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhan","family":"Debnath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6579-031X","authenticated-orcid":false,"given":"Samir Kumar","family":"Sil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2025.117534_b0005","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1007\/s10620-008-0601-7","article-title":"Global Histone H4 Acetylation and HDAC2 Expression in Colon Adenoma and Carcinoma","volume":"54","author":"Ashktorab","year":"2008","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.bcp.2025.117534_b0010","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.canlet.2013.03.003","article-title":"MiR-145 functions as a tumor suppressor by directly targeting histone deacetylase 2 in liver cancer","volume":"335","author":"Noh","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bcp.2025.117534_b0015","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1600-0463.2005.apm_04.x","article-title":"Increased expression of histone deacetylase 2 is found in human gastric cancer","volume":"113","author":"Song","year":"2005","journal-title":"APMIS"},{"key":"10.1016\/j.bcp.2025.117534_b0020","first-page":"1213","article-title":"HDAC2 overexpression correlates with aggressive clinicopathological features and DNA-damage response pathway of breast cancer","volume":"7","author":"Shan","year":"2017","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.bcp.2025.117534_b0025","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.oraloncology.2008.08.011","article-title":"Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients","volume":"45","author":"Chang","year":"2009","journal-title":"Oral Oncol."},{"key":"10.1016\/j.bcp.2025.117534_b0030","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1136\/gut.2009.180711","article-title":"HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA","volume":"58","author":"Fritsche","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.bcp.2025.117534_b0035","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.neuroscience.2018.02.026","article-title":"Suppression of HDAC2 in spinal cord alleviates mechanical hyperalgesia and restores KCC2 expression in a rat model of bone cancer pain","volume":"377","author":"Hou","year":"2018","journal-title":"Neuroscience"},{"key":"10.1016\/j.bcp.2025.117534_b0040","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.7314\/APJCP.2015.16.8.3543","article-title":"Differentially expressed genes in metastatic advanced Egyptian bladder cancer","volume":"16","author":"Zekri","year":"2015","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.bcp.2025.117534_b0045","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/sj.cdd.4401567","article-title":"Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1\/WAF1 expression, independent of histone deacetylase 1","volume":"12","author":"Huang","year":"2005","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bcp.2025.117534_b0050","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1470-2045(08)70004-4","article-title":"Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis","volume":"9","author":"Weichert","year":"2008","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bcp.2025.117534_b0055","article-title":"Control of cellular differentiation trajectories for cancer reversion","author":"Gong","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.bcp.2025.117534_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105695","article-title":"Histone deacetylase 2 selective inhibitors: a versatile therapeutic strategy as next generation drug target in cancer therapy","volume":"170","author":"Shetty","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bcp.2025.117534_b0065","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.3390\/molecules25071497","article-title":"Multitarget anticancer agents based on Histone deacetylase and protein kinase CK2 inhibitors","volume":"25","author":"Mart\u00ednez","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.bcp.2025.117534_b0070","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/449993a","article-title":"Mixing cocktails","volume":"449","author":"Sawyers","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2025.117534_b0075","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.drudis.2006.11.008","article-title":"Multi-target therapeutics: when the whole is greater than the sum of the parts","volume":"12","author":"Zimmermann","year":"2007","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bcp.2025.117534_b0080","doi-asserted-by":"crossref","first-page":"5232","DOI":"10.1158\/1078-0432.CCR-07-1385","article-title":"Targeted Agents: the rules of combination","volume":"13","author":"Kwak","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2025.117534_b0085","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/nrd2188","article-title":"The trouble with making combination drugs","volume":"5","author":"Simon","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2025.117534_b0090","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.1021\/jm058225d","article-title":"Designed Multiple ligands. an emerging drug discovery paradigm","volume":"48","author":"Morphy","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117534_b0095","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1158\/0008-5472.CAN-09-3360","article-title":"CUDC-101, a multitargeted inhibitor of Histone deacetylase, epidermal growth factor receptor, and human Epidermal growth factor receptor 2, exerts potent anticancer activity","volume":"70","author":"Lai","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2025.117534_b0100","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2015.00205","article-title":"Multi-target pharmacology: possibilities and limitations of the \u201cskeleton key approach\u201d from a medicinal chemist perspective","volume":"6","author":"Talevi","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117534_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114224","article-title":"Dual inhibitors of histone deacetylases and other cancer-related targets: a pharmacological perspective","volume":"182","author":"Gao","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117534_b0110","doi-asserted-by":"crossref","first-page":"4345","DOI":"10.1016\/j.bmcl.2006.05.051","article-title":"N-(1,2-Diphenylethyl)piperazines: a new class of dual serotonin\/noradrenaline reuptake inhibitor","volume":"16","author":"Fray","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2025.117534_b0115","doi-asserted-by":"crossref","first-page":"5640","DOI":"10.1021\/jm0605785","article-title":"New Opioid Designed Multiple Ligand from Dmt-Tic and Morphinan Pharmacophores","volume":"49","author":"Neumeyer","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117534_b0120","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1053\/j.seminoncol.2006.04.005","article-title":"New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors","volume":"33","author":"Faivre","year":"2006","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.bcp.2025.117534_b0125","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.tips.2009.09.007","article-title":"HDAC2: a critical factor in health and disease","volume":"30","author":"Kr\u00e4mer","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bcp.2025.117534_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113332","article-title":"Histone deacetylase 2: a potential therapeutic target for cancer and neurodegenerative disorders","volume":"216","author":"Gediya","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117534_b0135","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1016\/j.csbj.2023.03.016","article-title":"HDAC2 as a target for developing anti-cancer drugs","volume":"21","author":"Jo","year":"2023","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.bcp.2025.117534_b0140","series-title":"PJA2 suppresses colorectal cancer progression by controlling HDAC2 degradation and stability","author":"Chen","year":"2023"},{"key":"10.1016\/j.bcp.2025.117534_b0145","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1111\/jcmm.16186","article-title":"HDAC2 promotes the EMT of colorectal cancer cells and via the modular scaffold function of ENSG00000274093.1","volume":"25","author":"Qi","year":"2020","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.bcp.2025.117534_b0150","article-title":"The p300\/YY1\/miR-500a-5p\/HDAC2 signalling axis regulates cell proliferation in human colorectal cancer","volume":"10","author":"Tang","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2025.117534_b0155","doi-asserted-by":"crossref","DOI":"10.3892\/or.2019.7259","article-title":"FKBP3 mediates oxaliplatin resistance in colorectal cancer cells by regulating HDAC2 expression","author":"Tong","year":"2019","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bcp.2025.117534_b0160","doi-asserted-by":"crossref","DOI":"10.1590\/1414-431x20176103","article-title":"MicroRNA-455 suppresses the oncogenic function of HDAC2 in human colorectal cancer","volume":"50","author":"Mao","year":"2017","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.bcp.2025.117534_b0165","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00280-016-2979-9","article-title":"Histone deacetylase 2 regulates doxorubicin (Dox) sensitivity of colorectal cancer cells by targeting ABCB1 transcription","volume":"77","author":"Ye","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117534_b0170","doi-asserted-by":"crossref","first-page":"44505","DOI":"10.18632\/oncotarget.9887","article-title":"Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer","volume":"7","author":"Alzoubi","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2025.117534_b0175","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.3390\/jpm12101672","article-title":"Clinical significance of the Histone Deacetylase 2 (HDAC-2) Expression in Human Breast Cancer","volume":"12","author":"Garmpis","year":"2022","journal-title":"Journal of Personalized Medicine"},{"key":"10.1016\/j.bcp.2025.117534_b0180","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1093\/jjco\/hyw096","article-title":"HDAC2 overexpression is a poor prognostic factor of breast cancer patients with increased multidrug resistance-associated protein expression who received anthracyclines therapy","volume":"46","author":"Zhao","year":"2016","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2025.117534_b0185","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.7150\/thno.41008","article-title":"SRGN crosstalks with YAP to maintain chemoresistance and stemness in breast cancer cells by modulating HDAC2 expression","volume":"10","author":"Zhang","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.bcp.2025.117534_b0190","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-021-04047-2","article-title":"Histone deacetylase 2 knockout suppresses immune escape of triple-negative breast cancer cells via downregulating PD-L1 expression","volume":"12","author":"Xu","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bcp.2025.117534_b0195","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.3390\/cancers14153600","article-title":"HDAC2- and EZH2-Mediated Histone modifications Induce PDK1 Expression through miR-148a Downregulation in Breast Cancer Progression and Adriamycin Resistance","volume":"14","author":"Xie","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.bcp.2025.117534_b0200","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/nm.4092","article-title":"An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation","volume":"22","author":"Souroullas","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2025.117534_b0205","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1093\/carcin\/bgz067","article-title":"ARHGAP4 regulates the cell migration and invasion of pancreatic cancer by the HDAC2\/\u03b2-catenin signaling pathway","volume":"40","author":"Shen","year":"2019","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bcp.2025.117534_b0210","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1136\/gut.2009.180711","article-title":"HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA","volume":"58","author":"Fritsche","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.bcp.2025.117534_b0215","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s10495-023-01873-x","article-title":"USP43 impairs cisplatin sensitivity in epithelial ovarian cancer through HDAC2-dependent regulation of Wnt\/\u03b2-catenin signaling pathway","volume":"29","author":"Pei","year":"2023","journal-title":"Apoptosis"},{"key":"10.1016\/j.bcp.2025.117534_b0220","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3892\/ol.2016.5436","article-title":"HDAC2 regulates cell proliferation, cell cycle progression and cell apoptosis in esophageal squamous cell carcinoma EC9706 cells","volume":"13","author":"Li","year":"2016","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.bcp.2025.117534_b0225","doi-asserted-by":"crossref","DOI":"10.1186\/s13148-021-01068-8","article-title":"HDAC2 enhances esophageal squamous cell carcinoma development through down-regulating microRNA-503-5p and promoting CXCL10","volume":"13","author":"Li","year":"2021","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.bcp.2025.117534_b0230","article-title":"Histone deacetylase inhibitors inhibit lung adenocarcinoma metastasis via HDAC2\/YY1 mediated downregulation of Cdh1","volume":"13","author":"Wang","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2025.117534_b0235","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1007\/s11596-021-2389-z","article-title":"Roles of HDAC2, eIF5, and eIF6 in Lung Cancer Tumorigenesis","volume":"41","author":"Cai","year":"2021","journal-title":"Curr. Med. Sci."},{"key":"10.1016\/j.bcp.2025.117534_b0240","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.7150\/thno.18067","article-title":"FKBP3 Promotes Proliferation of Non-Small Cell Lung Cancer Cells through Regulating Sp1\/HDAC2\/p27","volume":"7","author":"Zhu","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.bcp.2025.117534_b0245","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-023-03973-3","article-title":"HDAC inhibitor ITF2357 reduces resistance of mutant-KRAS non-small cell lung cancer to pemetrexed through a HDAC2\/miR-130a-3p-dependent mechanism","volume":"21","author":"Cui","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bcp.2025.117534_b0250","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s10565-019-09459-7","article-title":"HDAC2-mediated upregulation of IL-6 triggers the migration of osteosarcoma cells","volume":"35","author":"Li","year":"2019","journal-title":"Cell Biol. Toxicol."},{"key":"10.1016\/j.bcp.2025.117534_b0255","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.18632\/oncotarget.27144","article-title":"Inhibition of histone deacetylase 2 reduces MDM2 expression and reduces tumor growth in dedifferentiated liposarcoma","volume":"10","author":"Seligson","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2025.117534_b0260","article-title":"HDAC2 links ubiquitination to tumor suppression in synovial sarcoma","volume":"8","author":"Cooley","year":"2021","journal-title":"Mol. Cell. Oncol."},{"key":"10.1016\/j.bcp.2025.117534_b0265","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.isci.2019.02.008","article-title":"HDAC2 Regulates Site-specific Acetylation of MDM2 and its UbiquitinationSignaling in Tumor suppression","volume":"13","author":"Patel","year":"2019","journal-title":"iScience"},{"key":"10.1016\/j.bcp.2025.117534_b0270","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1158\/1078-0432.CCR-15-1522","article-title":"SAR405838: a Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma","volume":"22","author":"Bill","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2025.117534_b0275","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-40776-y","article-title":"Epigenetic and molecular coordination between HDAC2 and SMAD3-SKI regulates essential brain tumour stem cell characteristics","volume":"14","author":"Bahia","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2025.117534_b0280","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.2401","article-title":"Histone deacetylase HDAC2 regulates microRNA\u2010125a expression in neuroblastoma","volume":"12","author":"Liu","year":"2022","journal-title":"Brain and Behavior"},{"key":"10.1016\/j.bcp.2025.117534_b0285","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/tox.23516","article-title":"MicroRNA\u2010455\u20103p functions as a tumor suppressor by targeting HDAC2 to regulate cell cycle in hepatocellular carcinoma","volume":"37","author":"Ma","year":"2022","journal-title":"Environ. Toxicol."},{"key":"10.1016\/j.bcp.2025.117534_b0290","article-title":"Inhibiting histone deacetylases suppresses glucose metabolism and hepatocellular carcinoma growth by restoring FBP1 expression","volume":"7","author":"Yang","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2025.117534_b0295","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.3892\/mmr.2015.4676","article-title":"1,25(OH)2D3 inhibits the progression of hepatocellular carcinoma via downregulating HDAC2 and upregulating P21(WAFI\/CIP1)","volume":"13","author":"Huang","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.bcp.2025.117534_b0300","doi-asserted-by":"crossref","first-page":"8089","DOI":"10.18632\/oncotarget.3512","article-title":"MicroRNA-31 functions as a tumor suppressor by regulating cell cycle and epithelial-mesenchymal transition regulatory proteins in liver cancer","volume":"6","author":"Kim","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2025.117534_b0305","article-title":"High Histone Deacetylase 2\/3 Expression in Non-Functioning Pituitary Tumors","volume":"12","author":"Zhao","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2025.117534_b0310","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jid.2021.05.026","article-title":"HDAC1\/2 Control Proliferation and Survival in Adult Epidermis and Pre\u2012Basal Cell Carcinoma through p16 and p53","volume":"142","author":"Zhu","year":"2021","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.bcp.2025.117534_b0315","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1111\/cas.14868","article-title":"GPR126 regulates colorectal cancer cell proliferation by mediating HDAC2 and GLI2 expression","volume":"112","author":"Cui","year":"2021","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bcp.2025.117534_b0320","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-020-01783-9","article-title":"HDAC2 inhibits EMT-mediated cancer metastasis by downregulating the long noncoding RNA H19 in colorectal cancer","volume":"39","author":"Hu","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2025.117534_b0325","doi-asserted-by":"crossref","first-page":"7123","DOI":"10.18632\/oncotarget.3344","article-title":"Sumoylation of HDAC2 promotes NF-\u03baB-dependent gene expression","volume":"6","author":"Wagner","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2025.117534_b0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2019.100645","article-title":"The multi-factorial nature of clinical multidrug resistance in cancer","volume":"46","author":"Assaraf","year":"2019","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.bcp.2025.117534_b0335","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1016\/j.addr.2013.09.018","article-title":"Multidrug resistance: Physiological principles and nanomedical solutions","volume":"65","author":"Kunjachan","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bcp.2025.117534_b0340","article-title":"The Emerging Roles of Rad51 in Cancer and its potential as a Therapeutic Target","volume":"12","author":"Wang","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2025.117534_b0345","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ctrv.2014.10.006","article-title":"Targeting homologous recombination, new pre-clinical and clinical therapeutic combinations inhibiting RAD51","volume":"41","author":"Ward","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bcp.2025.117534_b0350","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.18632\/oncotarget.1923","article-title":"Rad51 supports triple negative breast cancer metastasis","volume":"5","author":"Wiegmans","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2025.117534_b0355","article-title":"ABC transporters affects tumor immune microenvironment to regulate cancer immunotherapy and multidrug resistance","volume":"66","author":"Fan","year":"2022","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.bcp.2025.117534_b0360","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20191764","article-title":"Long non-coding RNA ARAP1-AS1 accelerates cell proliferation and migration in breast cancer through miR-2110\/HDAC2\/PLIN1 axis","volume":"40","author":"Lu","year":"2020","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.bcp.2025.117534_b0365","article-title":"HDAC2\u2010Mediated METTL3 delactylation promotes DNA damage repair and chemotherapy resistance in Triple\u2010Negative breast cancer","author":"He","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.bcp.2025.117534_b0370","doi-asserted-by":"crossref","DOI":"10.1186\/s12935-017-0442-6","article-title":"The role of REST and HDAC2 in epigenetic dysregulation of Nav1.5 and nNav1.5 expression in breast cancer","volume":"17","author":"Kamarulzaman","year":"2017","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.bcp.2025.117534_b0375","article-title":"Lamin B1 Overexpression Promotes Breast Cancer Growth via increasing H3K9ac Modification through HDAC2 Inhibition","author":"Jia","year":"2022","journal-title":"SSRN Electron. J."},{"key":"10.1016\/j.bcp.2025.117534_b0380","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1158\/0008-5472.CAN-20-3209","article-title":"HDAC2 Facilitates Pancreatic Cancer Metastasis","volume":"82","author":"Krau\u00df","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2025.117534_b0385","doi-asserted-by":"crossref","first-page":"334","DOI":"10.15252\/embr.201541922","article-title":"HDAC 2 promotes loss of primary cilia in pancreatic ductal adenocarcinoma","volume":"18","author":"Kobayashi","year":"2016","journal-title":"EMBO Rep."},{"key":"10.1016\/j.bcp.2025.117534_b0390","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s10565-022-09759-5","article-title":"Human umbilical cord mesenchymal stem cell-derived extracellular vesicles carrying miR-655-3p inhibit the development of esophageal cancer by regulating the expression of HIF-1\u03b1 via a LMO4\/HDAC2-dependent mechanism","volume":"39","author":"Chen","year":"2022","journal-title":"Cell Biol. Toxicol."},{"key":"10.1016\/j.bcp.2025.117534_b0395","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1016\/j.athoracsur.2004.05.037","article-title":"ERBB2 amplifications in esophageal adenocarcinoma","volume":"78","author":"Dahlberg","year":"2004","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.bcp.2025.117534_b0400","doi-asserted-by":"crossref","DOI":"10.1177\/09603271221084672","article-title":"MicroRNA-122-5p prevents proliferation and promotes apoptosis of hepatic stellate cells by suppressing the cellular-Abelsongene\/histone deacetylases 2 pathway","volume":"41","author":"Wu","year":"2022","journal-title":"Hum. Exp. Toxicol."},{"key":"10.1016\/j.bcp.2025.117534_b0405","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/kjm2.12558","article-title":"Silencing of lncRNA CRNDE attenuates nonsmall\u2010cell lung cancer progression by mediating the miR\u2010455\u20103p\/HDAC2 axis","volume":"38","author":"Li","year":"2022","journal-title":"Kaohsiung J. Med. Sci."},{"key":"10.1016\/j.bcp.2025.117534_b0410","first-page":"1","article-title":"MicroRNA-31 Function as a Suppressor was Regulated by Epigenetic Mechanisms in Gastric Cancer","volume":"2017","author":"Wei","year":"2017","journal-title":"Biomed Res. Int."},{"key":"10.1016\/j.bcp.2025.117534_b0415","doi-asserted-by":"crossref","first-page":"11336","DOI":"10.1080\/21655979.2022.2068921","article-title":"GATA binding protein 1 recruits histone deacetylase 2 to the promoter region of nuclear receptor binding protein 2 to affect the tumor microenvironment and malignancy of thyroid carcinoma","volume":"13","author":"Li","year":"2022","journal-title":"Bioengineered"},{"key":"10.1016\/j.bcp.2025.117534_b0420","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1038\/s41388-017-0090-2","article-title":"TBX3 promotes proliferation of papillary thyroid carcinoma cells through facilitating PRC2-mediated p57KIP2 repression","volume":"37","author":"Li","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2025.117534_b0425","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/odi.12641","article-title":"Immunoexpression of HDAC1, HDAC2, and HAT1 in actinic cheilitis and lip squamous cell carcinoma","volume":"23","author":"Chrun","year":"2017","journal-title":"Oral Dis."},{"key":"10.1016\/j.bcp.2025.117534_b0430","article-title":"Selective targeting of HDAC1\/2 elicits anticancer effects through Gli1 acetylation in preclinical models of SHH Medulloblastoma","volume":"7","author":"Coni","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2025.117534_b0435","doi-asserted-by":"crossref","DOI":"10.1186\/s40169-020-0260-7","article-title":"EGFR\u2010vIII downregulated H2AZK4\/7AC though the PI3K\/AKT\u2010HDAC2 axis to regulate cell cycle progression","volume":"9","author":"Zhao","year":"2020","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.bcp.2025.117534_b0440","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-022-02460-9","article-title":"YTHDC1 is downregulated by the YY1\/HDAC2 complex and controls the sensitivity of ccRCC to sunitinib by targeting the ANXA1-MAPK pathway","volume":"41","author":"Li","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2025.117534_b0445","first-page":"539","article-title":"miR-490-3p modulates the progression of prostate cancer through regulating histone deacetylase2","volume":"23","author":"Fan","year":"2019","journal-title":"PubMed"},{"key":"10.1016\/j.bcp.2025.117534_b0450","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/onc.2016.319","article-title":"Beta-adrenergic signaling promotes tumor angiogenesis and prostate cancer progression through HDAC2- mediated suppression of thrombospondin-1","volume":"36","author":"Hulsurkar","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2025.117534_b0455","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/2211-5463.12585","article-title":"Histone deacetylase 2 is involved in DNA damage\u2010mediated cell death of human osteosarcoma cells through stimulation of the ATM\/p53 pathway","volume":"9","author":"Sun","year":"2019","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.bcp.2025.117534_b0460","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-018-0978-x","article-title":"HDAC2 depletion promotes osteosarcoma\u2019s stemness both in vitro and in vivo: a study on a putative new target for CSCs directed therapy","volume":"37","author":"La Noce","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2025.117534_b0465","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1182\/blood-2005-02-0553","article-title":"MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy","volume":"106","author":"Kojima","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2025.117534_b0470","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1158\/1078-0432.CCR-15-1522","article-title":"SAR405838: a Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma","volume":"22","author":"Bill","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2025.117534_b0475","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1158\/0008-5472.CAN-17-0392","article-title":"AXL-Driven EMT state as a targetable conduit in cancer","volume":"77","author":"Antony","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2025.117534_b0480","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1158\/1535-7163.MCT-13-1083","article-title":"Axl Kinase as a key target for oncology: focus on small molecule inhibitors","volume":"13","author":"Feneyrolles","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2025.117534_b0485","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3322\/caac.21411","article-title":"Treatment of renal cell carcinoma: current status and future directions, CA a","volume":"67","author":"Barata","year":"2017","journal-title":"Cancer J. Clin."},{"key":"10.1016\/j.bcp.2025.117534_b0490","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1021\/acs.jmedchem.5b01273","article-title":"AXL inhibitors in Cancer: a Medicinal Chemistry perspective","volume":"59","author":"Myers","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117534_b0495","doi-asserted-by":"crossref","first-page":"9953","DOI":"10.3390\/ijms22189953","article-title":"Therapeutic targeting of the GAS6\/AXL signaling pathway in cancer","volume":"22","author":"Tanaka","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2025.117534_b0500","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.3390\/cancers13071521","article-title":"The role of the receptor tyrosine kinase AXL in carcinogenesis and development of therapeutic resistance: an overview of molecular mechanisms and future applications","volume":"13","author":"Wium","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bcp.2025.117534_b0505","first-page":"94","article-title":"AXL and MET in Hepatocellular Carcinoma: a Systematic Literature Review, Liver","volume":"11","author":"Hsu","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.bcp.2025.117534_b0510","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.canlet.2022.01.007","article-title":"Chidamide and mitomycin C exert synergistic cytotoxic effects against bladder cancer cells in vitro and suppress tumor growth in a rat bladder cancer model","volume":"530","author":"Wang","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bcp.2025.117534_b0515","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.742561","article-title":"Emerging advances in combinatorial treatments of epigenetically Altered Pediatric High-Grade H3K27M Gliomas","volume":"12","author":"Leszczynska","year":"2021","journal-title":"Front. Genet."},{"key":"10.1016\/j.bcp.2025.117534_b0520","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1158\/1078-0432.CCR-19-3538","article-title":"Combined therapy of AXL and HDAC inhibition reverses mesenchymal transition in diffuse intrinsic pontine glioma","volume":"26","author":"Meel","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2025.117534_b0525","article-title":"Discovery of novel and potent dual-targeting AXL\/HDAC2 inhibitors for colorectal cancer treatment via structure-based pharmacophore modelling, virtual screening, and molecular docking, molecular dynamics simulation studies, and biological evaluation","volume":"39","author":"Qiao","year":"2023","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117534_b0530","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/256547a0","article-title":"Genetic control of cell size at cell division in yeast","volume":"256","author":"Nurse","year":"1975","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2025.117534_b0535","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.advenzreg.2009.12.001","article-title":"Identification of substrates for cyclin dependent kinases","volume":"50","author":"Errico","year":"2010","journal-title":"Adv. Enzyme Regul."},{"key":"10.1016\/j.bcp.2025.117534_b0540","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/S0140-6736(06)69780-8","article-title":"Acute myeloid leukaemia","volume":"368","author":"Estey","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2025.117534_b0545","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1021\/acs.jmedchem.7b01261","article-title":"Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia","volume":"61","author":"Wang","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117534_b0550","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/sj.leu.2402535","article-title":"Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA)","volume":"16","author":"Almenara","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.bcp.2025.117534_b0555","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1158\/1535-7163.MCT-10-0562","article-title":"Combination of Vorinostat and Flavopiridol is Selectively Cytotoxic to Multidrug-Resistant neuroblastoma Cell Lines with Mutant TP53","volume":"9","author":"Huang","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2025.117534_b0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112073","article-title":"Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity","volume":"189","author":"Cheng","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117534_b0565","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112322","article-title":"Design, synthesis and biological evaluation of novel histone deacetylase1\/2 (HDAC1\/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer","volume":"198","author":"Yun","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117534_b0570","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrc3409","article-title":"Protein arginine methyltransferases and cancer","volume":"13","author":"Yang","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bcp.2025.117534_b0575","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1101\/gad.1975811","article-title":"Regulated recruitment of tumor suppressor BRCA1 to the p21 gene by coactivator methylation","volume":"25","author":"Lee","year":"2011","journal-title":"Genes Dev."},{"key":"10.1016\/j.bcp.2025.117534_b0580","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.tcb.2020.12.010","article-title":"CARM1\/PRMT4: making its Mark beyond its Function as a Transcriptional Coactivator","volume":"31","author":"Suresh","year":"2021","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.bcp.2025.117534_b0585","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1093\/nar\/gkq1246","article-title":"Automethylation of CARM1 allows coupling of transcription and mRNA splicing","volume":"39","author":"Kuhn","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bcp.2025.117534_b0590","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-20080-9","article-title":"Pontin arginine methylation by CARM1 is crucial for epigenetic regulation of autophagy","volume":"11","author":"Yu","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2025.117534_b0595","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000027094","article-title":"The protein arginine methyltransferases (PRMTs) PRMT1 and CARM1 as candidate epigenetic drivers in prostate cancer progression","volume":"100","author":"Grypari","year":"2021","journal-title":"Medicine"},{"key":"10.1016\/j.bcp.2025.117534_b0600","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-10-197","article-title":"Differential CARM1 expression in prostate and colorectal cancers","volume":"10","author":"Kim","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bcp.2025.117534_b0605","doi-asserted-by":"crossref","first-page":"16650","DOI":"10.1021\/acs.jmedchem.1c01308","article-title":"Structure-based discovery of potent CARM1 inhibitors for solid tumor and cancer immunology therapy","volume":"64","author":"Zhang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117534_b0610","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2023.2241118","article-title":"Discovery and biological evaluation of novel CARM1\/HDAC2 dual-targeting inhibitors with anti-prostate cancer agents","volume":"38","author":"Liang","year":"2023","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117534_b0615","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.4155\/fmc-2022-0252","article-title":"Recent advances in ATM inhibitors as potential therapeutic agents","volume":"14","author":"Dong","year":"2022","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.bcp.2025.117534_b0620","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3858\/emm.2010.42.3.020","article-title":"ATM modulates transcription in response to histone deacetylase inhibition as part of its DNA damage response","volume":"42","author":"Jang","year":"2010","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.bcp.2025.117534_b0625","doi-asserted-by":"crossref","first-page":"7304","DOI":"10.1021\/acs.jmedchem.2c02104","article-title":"Design and Optimization of Novel Benzimidazole- and Imidazo[4,5-b]pyridine-based ATM Kinase Inhibitors with Subnanomolar Activities","volume":"66","author":"Dimitrov","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117534_b0630","doi-asserted-by":"crossref","first-page":"838","DOI":"10.4161\/cc.4.6.1742","article-title":"ATM activation in normal human tissues and testicular cancer","volume":"4","author":"Bartkova","year":"2005","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bcp.2025.117534_b0635","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.18632\/oncotarget.27723","article-title":"ATM inhibition overcomes resistance to histone deacetylase inhibitor due to p21 induction and cell cycle arrest","volume":"11","author":"Scotto","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2025.117534_b0640","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2018.00092","article-title":"Combination therapy with Histone Deacetylase inhibitors (HDACI) for the treatment of cancer: Achieving the full therapeutic potential of HDACI","volume":"8","author":"Suraweera","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2025.117534_b0645","doi-asserted-by":"crossref","first-page":"5283","DOI":"10.2147\/DDDT.S479113","article-title":"Discovery of a Novel and Potent Dual-Targeting Inhibitor of ATM and HDAC2 through Structure-based Virtual Screening for the Treatment of Testicular Cancer","volume":"18","author":"Ruan","year":"2024","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.bcp.2025.117534_b0650","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ejmech.2018.10.050","article-title":"Computer-aided design, synthesis and biological characterization of novel inhibitors for PKMYT1","volume":"161","author":"Najjar","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117534_b0655","doi-asserted-by":"crossref","DOI":"10.3892\/or.2018.6371","article-title":"Protein kinase, membrane\u2013associated tyrosine\/threonine\u00ef\u00bf\u00bd1 is associated with the progression of colorectal cancer","author":"Jeong","year":"2018","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bcp.2025.117534_b0660","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cancergen.2017.06.002","article-title":"Gene expression profiling, pathway analysis and subtype classification reveal molecular heterogeneity in hepatocellular carcinoma and suggest subtype specific therapeutic targets","volume":"216\u2013217","author":"Agarwal","year":"2017","journal-title":"Cancer Genet."},{"key":"10.1016\/j.bcp.2025.117534_b0665","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/leu.2014.296","article-title":"A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations","volume":"29","author":"Zhou","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.bcp.2025.117534_b0670","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1491497","article-title":"Discovery of novel and highly potent dual-targeting PKMYT1\/HDAC2 inhibitors for hepatocellular carcinoma through structure-based virtual screening and biological evaluation","volume":"15","author":"Yang","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117534_b0675","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ejmech.2017.09.063","article-title":"Synthesis, antiproliferative, anti-tubulin activity, and docking study of new 1,2,4-triazoles as potential combretastatin analogues","volume":"141","author":"Mustafa","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117534_b0680","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111697","article-title":"Potent combretastatin A-4 analogs containing 1, 2, 4-triazole: synthesis, antiproliferative, anti tubulin activity, and docking study","volume":"183","author":"Mustafa","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117534_b0685","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113569","article-title":"A first-in-class anticancer dual HDAC2\/FAK inhibitors bearing hydroxamates\/benzamides capped by pyridinyl-1,2,4-triazoles","volume":"222","author":"Mustafa","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117534_b0690","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.ejmech.2018.08.073","article-title":"HDAC as onco target: reviewing the synthetic approaches with SAR study of their inhibitors","volume":"158","author":"Sangwan","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117534_b0695","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.127965","article-title":"Discovery of antiproliferative and anti-FAK inhibitory activity of 1,2,4-triazole derivatives containing acetamido carboxylic acid skeleton","volume":"40","author":"Mustafa","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2025.117534_b0700","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1007\/s00044-012-0306-5","article-title":"Synthesis, molecular modeling, and biological evaluation of 1,2,4-triazole derivatives containing pyridine as potential anti-tumor agents","volume":"22","author":"Zhang","year":"2012","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.bcp.2025.117534_b0705","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejmech.2018.01.021","article-title":"Spirohydantoins and 1,2,4-triazole-3-carboxamide derivatives as inhibitors of histone deacetylase: Design, synthesis, and biological evaluation","volume":"146","author":"Aboeldahab","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117534_b0710","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.ejmech.2016.01.013","article-title":"Identification of N-(6-mercaptohexyl)-3-(4-pyridyl)-1H-pyrazole-5-carboxamide and its disulfide prodrug as potent histone deacetylase inhibitors with in vitro and in vivo anti-tumor efficacy","volume":"109","author":"Wen","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117534_b0715","doi-asserted-by":"crossref","first-page":"8026","DOI":"10.1021\/jm5008962","article-title":"Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors","volume":"57","author":"Tang","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117534_b0720","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.bmcl.2016.01.022","article-title":"Dissecting structure\u2013activity-relationships of crebinostat: Brain penetrant HDAC inhibitors for neuroepigenetic regulation","volume":"26","author":"Ghosh","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2025.117534_b0725","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/nrc3792","article-title":"FAK in cancer: mechanistic findings and clinical applications","volume":"14","author":"Sulzmaier","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bcp.2025.117534_b0730","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1002\/ijc.29522","article-title":"Targeting FAK scaffold functions inhibits human renal cell carcinoma growth","volume":"137","author":"B\u00e9raud","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bcp.2025.117534_b0735","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113592","article-title":"5-Aminonaphthalene derivatives as selective nonnucleoside nuclear receptor binding SET domain-protein 2 (NSD2) inhibitors for the treatment of multiple myeloma","volume":"222","author":"Wang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117534_b0740","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.600514","article-title":"Overexpression of EZH2\/NSD2 Histone methyltransferase axis predicts poor prognosis and accelerates tumor progression in Triple-negative breast cancer","volume":"10","author":"Gao","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2025.117534_b0745","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1038\/ng.2777","article-title":"Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia","volume":"45","author":"Jaffe","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bcp.2025.117534_b0750","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/leu.2013.204","article-title":"Point mutation E1099K in MMSET\/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies","volume":"28","author":"Oyer","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.bcp.2025.117534_b0755","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-021-04267-6","article-title":"Identification of histone methyltransferase NSD2 as an important oncogenic gene in colorectal cancer","volume":"12","author":"Zhao","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bcp.2025.117534_b0760","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1038\/s41388-021-01747-z","article-title":"NSD2 promotes tumor angiogenesis through methylating and activating STAT3 protein","volume":"40","author":"Song","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2025.117534_b0765","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1128\/MCB.00204-12","article-title":"Histone methyltransferase NSD2\/MMSET mediates constitutive NF-\u039aB signaling for cancer cell proliferation, survival, and tumor growth via a Feed-Forward loop","volume":"32","author":"Yang","year":"2012","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bcp.2025.117534_b0770","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1038\/onc.2012.297","article-title":"The histone methyltransferase MMSET\/WHSC1 activates TWIST1 to promote an epithelial\u2013mesenchymal transition and invasive properties of prostate cancer","volume":"32","author":"Ezponda","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2025.117534_b0775","doi-asserted-by":"crossref","first-page":"6837","DOI":"10.2147\/OTT.S259873","article-title":"The Role of Methyltransferase NSD2 as a potential Oncogene in Human Solid Tumors","volume":"13","author":"Chen","year":"2020","journal-title":"OncoTargets and Therapy"},{"key":"10.1016\/j.bcp.2025.117534_b0780","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1182\/blood-2009-03-213496","article-title":"Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin a and the histone deacetylase inhibitor panobinostat against human AML cells","volume":"114","author":"Fiskus","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2025.117534_b0785","article-title":"Novel dual-targeting inhibitors of NSD2 and HDAC2 for the treatment of liver cancer: structure-based virtual screening, molecular dynamics simulation, and in vitro and in vivo biological activity evaluations","volume":"39","author":"Jin","year":"2023","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117534_b0790","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1158\/1078-0432.CCR-12-0055","article-title":"Cancer Network Disruption by a Single Molecule Inhibitor Targeting both Histone Deacetylase activity and Phosphatidylinositol 3-Kinase Signaling","volume":"18","author":"Qian","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2025.117534_b0795","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.3324\/haematol.2019.233445","article-title":"The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia","volume":"106","author":"Li","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.bcp.2025.117534_b0800","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.3324\/haematol.2017.172882","article-title":"CUDC-907 in relapsed\/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial","volume":"102","author":"Oki","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.bcp.2025.117534_b0805","article-title":"Therapeutic strategies of dual-target small molecules to overcome drug resistance in cancer therapy, Biochimica Et Biophysica Acta (BBA) - Reviews on","author":"Ye","year":"1878","journal-title":"Cancer"},{"key":"10.1016\/j.bcp.2025.117534_b0810","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1002\/med.22057","article-title":"Rethinking therapeutic strategies of dual\u2010target drugs: an update on pharmacological small\u2010molecule compounds in cancer","volume":"44","author":"Yang","year":"2024","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bcp.2025.117534_b0815","doi-asserted-by":"crossref","first-page":"11260","DOI":"10.1021\/acs.jmedchem.9b01489","article-title":"Synthesis of Peptoid-based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties","volume":"62","author":"Krieger","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117534_b0820","first-page":"1","article-title":"Repurposing of DrugBank molecules as dual non-hydroxamate HDAC8 and HDAC2 inhibitors by pharmacophore modeling, molecular docking, and molecular dynamics studies","author":"Sarkar","year":"2024","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.bcp.2025.117534_b0825","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2019.07.052","article-title":"Novel \u03b1,\u03b2-unsaturated hydroxamic acid derivatives overcome cisplatin resistance","volume":"27","author":"Pflieger","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117534_b0830","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1016\/j.bmcl.2017.08.011","article-title":"Rational design, synthesis and preliminary antitumor activity evaluation of a chlorambucil derivative with potent DNA\/HDAC dual-targeting inhibitory activity","volume":"27","author":"Xie","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225007993?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225007993?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:20:01Z","timestamp":1781065201000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295225007993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":166,"alternative-id":["S0006295225007993"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117534","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unfolding the role of HDAC2 in the epigenetic puzzle of cancer: A dive into molecular pathways for precision-driven multi-target therapy","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117534","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117534"}}